PDS Biotech Appoints John Dawson, Deborah Ramsdell and Bruce Wendel to Board

Bitget2026/10/20 12:04

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

PDS Biotech appointed former Oxford Biomedica CEO John Dawson to its board, effective October 18, 2026.
Fellow appointee Deborah Ramsdell is CEO of Pluvia Biotech, having previously led Phoenicis Therapeutics and Valerion Therapeutics.
Bruce Wendel also joined the board; he previously served as executive vice president of corporate development at Bristol-Myers Squibb.
Stephen Glover and Kamil Ali-Jackson resigned from the board, effective October 18, 2026.
Gregory Freitag and Otis Brawley also stepped down on the same date.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. PDS Biotechnology Corporation published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610200800PRIMZONEFULLFEED9849048) on October 20, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

PDS Biotech Appoints John Dawson, Deborah Ramsdell and Bruce Wendel to Board

You may also like

Crypto prices